Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

Journal of Experimental Medicine

Volumn 201, Issue 9, 2005, Pages 1479-1486

  Pascual, Virginia ^a,b   Allantaz, Florence ^a   Arce, Edsel ^a   Punaro, Marilynn ^b,c   Banchereau, Jacques ^a  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1BETA; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ERYTHEMA; FEMALE; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOTENSION; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; MALE; NUCLEOTIDE SEQUENCE; ONSET AGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SYMPTOM; VIRUS INFECTION; VOMITING;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; CHEMOKINES; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; LEUKOCYTES, MONONUCLEAR; MALE; MICROARRAY ANALYSIS; PREDNISONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERUM; SIALOGLYCOPROTEINS;

EID: 18644385243     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20050473     Document Type: Article

References (34)

1. Cassidy, J.T., and R.E. Petty. 2001. Textbook of Pediatric Rheumatology. W.B. Saunders, Philadelphia, PA. 976 pp.
2. Wallace, C.A., and J.E. Levinson. 1991. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum. Dis. Clin. North Am. 17:891-905.
3. Ravelli, A., and A. Martini. 2003. Early predictors of outcome in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 21:S89-S93.
4. Modesto, C., P. Woo, J. Garcia-Consuegra, R. Merino, M. Garcia-Granero, C. Arnal, and A.M. Prieur. 2001. Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for a bad prognosis. Clin. Exp. Rheumatol. 19:211-217.
5. Ravelli, A. 2004. Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 22:271-275.
6. Spiegel, L.R., R. Schneider, B.A. Lang, N. Birdi, E.D. Silverman, R.M. Laxer, D. Stephens, and B.M. Feldman. 2000. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 43:2402-2409.
7. Lomater, C., V. Gerloni, M. Gattinara, J. Mazzotti, R. Cimaz, and F. Fantini. 2000. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 27:491-496.
8. Bowyer, S.L., P.A. Roettcher, G.C. Higgins, B. Adams, L.K. Myers, C. Wallace, R. Rennebohm, T.L. Moore, P.M. Pepmueller, C. Spencer, et al. 2003. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J. Rheumatol. 30:394-400.
9. de Benedetti, F., M. Massa, P. Robbioni, A. Ravelli, G.R. Burgio, and A. Martini. 1991. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 34:1158-1163.
10. Adebajo, A.O., and M.A. Hall. 1998. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br. J. Rheumatol. 37:1240-1242.
11. Lehman, T.J. 2000. Clinical trials for the treatment of systemic onset juvenile rheumatoid arthritis-juvenile idiopathic arthritis. Curr. Rheumatol. Rep. 2:313-315.
12. Lehman, T.J., K.H. Striegel, and K.B. Onel. 2002. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J. Pediatr. 140:125-127.
13. Lovell, D.J., E.H. Giannini, A. Reiff, G.D. Cawkwell, E.D. Silverman, J.J. Nocton, L.D. Stein, A. Gedalia, N.T. Ilowite, C.A. Wallace, et al. 2000. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342:763-769.
14. Lovell, D.J., E.H. Giannini, A. Reiff, O.Y. Jones, R. Schneider, J.C. Olson, L.D. Stein, A. Gedalia, N.T. Ilowite, C.A. Wallace, et al. 2003. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 48:218-226.
15. Homeff, G., H. Schmeling, T. Biedermann, I. Foeldvari, G. Ganser, H.J. Girschick, T. Hosbach, H.I. Huppertz, R. Keitzer, R.M. Kuester, et al. 2004. The German etanercept registry for treatment of juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 63:1638-1644.
16. Quartier, P., P. Taupin, F. Bourdeaut, I. Lemelle, P. Pillet, M. Bost, J. Sibilia, I. Kone-Paut, S. Gandon-Laloum, M. LeBideau, et al. 2003. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 48:1093-1101.
17. Blanco, P., A.K. Palucka, M. Gill, V. Pascual, and J. Banchereau. 2001. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 294:1540-1543.
18. Bennett, L., A.K. Palucka, E. Arce, V. Cantrell, J. Borvak, J. Banchereau, and V. Pascual. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197:711-723.
19. Moser, B., M. Wolf, A. Walz, and P. Loetscher. 2004. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25:75-84.
20. Saeki, T., and A. Naya. 2003. CCR1 chemokine receptor antagonist. Curr. Pharm. Des. 9:1201-1208.
21. Andrei, C., P. Margiocco, A. Poggi, L.V. Lotti, M.R. Torrisi, and A. Rubartelli. 2004. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: implications for inflammatory processes. Proc. Natl. Acad. Sci. USA. 101:9745-9750.
22. Shoham, N.G., M. Centola, E. Mansfield, K.M. Hull, G. Wood, C.A. Wise, and D.L. Kastner. 2003. Pyrin binds the PSTPlP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl. Acad. Sci. USA. 100:13501-13506.
23. Aksentijevich, I., M. Nowak, M. Mallah, J.J. Chae, W.T. Watford, S.R. Hofmann, L. Stein, R. Russo, D. Goldsmith, P. Dent, et al. 2002. De novo ClAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46:3340-3348.
24. Hawkins, P.N., H.J. Lachmann, E. Aganna, and M.F. McDermott. 2004. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50:607-612.
25. Hoffman, H.M., S. Rosengren, D.L. Boyle, J.Y. Cho, J. Nayar, J.L. Mueller, J.P. Anderson, A.A. Wanderer, and G.S. Firestein. 2004. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet. 364:1779-1785.
26. Dinarello, C.A. 2002. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. 20:S1-13.
27. Saijo, S., M. Asano, R. Horai, H. Yamamoto, and Y. Iwakura. 2002. Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum. 46:533-544.
28. Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, and Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191:313-320.
29. Genovese, M.C., S. Cohen, L. Moreland, D. Lium, S. Robbins, R. Newmark, and P. Bekker. 2004. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50:1412-1419.
30. Buch, M.H., S.J. Bingham, Y. Seto, D. McGonagle, V. Bejarano, J. White, and P. Emery. 2004. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum. 50:725-728.
31. Muller, K., E.B. Herner, A. Stagg, K. Bendtzen, and P. Woo. 1998. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br. J. Rheumatol. 37:562-569.
32. Muzaffer, M.A., J.M. Dayer, B.M. Feldman, W. Pruzanski, P. Roux-Lombard, R. Schneider, R.M. Laxer, and E.D. Silverman. 2002. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. J. Rheumatol. 29:1071-1078.
33. Verbsky, J.W., and A.J. White. 2004. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 31:2071-2075.
34. Cassidy, J.T., J.E. Levinson, J.C. Bass, J. Baum, E.J. Brewer Jr., C.W. Fink, V. Hanson, J.C. Jacobs, A.T. Masi, J.G. Schaller, et al. 1986. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum. 29:274-281.